Sanofi, AstraZeneca’s RSV antibody

admin Avatar

Sanofi is ex­pect­ing sup­ply con­straints of its in­fant RSV an­ti­body Bey­for­tus, which it co-de­vel­oped with As­traZeneca, in the first quar­ter of this year. While it is ex­pect­ing to boost pro­duc­tion, the com­pa­ny says it’s too ear­ly to say by how much.

The French phar­ma is work­ing to lift any man­u­fac­tur­ing bot­tle­necks and “un­lock ca­pac­i­ty” to tack­le sup­ply con­straints, but “the ques­tion is how much progress we can make in 2024,” CEO Paul Hud­son not­ed on a me­dia call Thurs­day morn­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

admin Avatar

Leave a Reply

Your email address will not be published. Required fields are marked *

More Articles & Posts

xcbxdf xcbxdf xcbxdf |https://elearning.psspbenin.org/|https://regalautogroup.net/|https://vmediacom.com/|http://www.icrea.de/|http://pape-academy.de/|https://graha.id/|https://maxdesain.com/|https://www.nextgtool.com/|https://www.theeducationpoint.in/|https://www.healthyactivities.us/|https://dw9.it/|https://digitalexponents.co.in/|https://safeandsecuretechsol.com/|https://sahayasamvrudhiseva.com/|https://sprinteriors.co.in/|https://vestininfra.com/|https://oruganti.co.in/|https://conceptonetechnology.com/|https://cycloneproduct.com/|https://huperoptik-me.com/|https://motorworksco.com/|https://dreamstudio.agency|https://elang-indonesia.com/|https://fullmetal.vc|https://gengennygen.com/|https://kcadvisory.co/|https://lugiami.gg/|https://starnet.global/|http://miraclelounges.com/|https://manhattanexterminators.biz/|https://orieuro.com|https://joebluepestcontrol.com/|http://lgigkp.com/|https://bible-teacher.org/|https://xn--energibyrn-95a.com/|https://posadaeljecho.com/|https://culinan777.online/|https://www.proxelan.hu|https://nossasenhoradalapa.org.br/|https://vkbii.com/